

WEBVTT

Karen Gainey: Just quickly a reminder that you'll notice we're recording this

23

00:02:13.180 --> 00:02:25.709

Karen Gainey: for just the audio only, and Zoom is going to transcribe the interview. And as I'm offering to anyone, if you'd like to have a look at the transcription after this, just to check you're happy with it.

24

00:02:25.930 --> 00:02:35.540

Karen Gainey: Clarify the context of anything you've said. You're very welcome to, but don't feel obliged at all. I'm sure you're very busy

25

00:02:35.740 --> 00:02:45.150

Karen Gainey: before we get started. Did you have any questions you wanted to ask? Or would you like me to give you an overview of again of what I'm doing and why

26

00:02:45.150 --> 00:02:49.299

Participant 19: Yeah, it'd be good to have an overview. I did read the material, but it's been a couple of weeks since then.

27

00:02:49.300 --> 00:02:51.524

Karen Gainey: A little while. Yeah, sure.

28

00:02:53.920 --> 00:02:58.138

Karen Gainey: so basically, this is the final project in my Phd,

29

00:02:58.880 --> 00:03:24.070

Karen Gainey: which is on plain language summaries. So I started off with a scoping review, looking at guidelines, and then followed that up with a I guess compliance audit, comparing the guidelines with actual plain language, summaries in journals to see how closely they compared, and that was published a little while ago, and quite varying mixed results.

30

00:03:24.070 --> 00:03:33.309

Karen Gainey: and just about to be published, is a very similar project to this, where I interviewed people who read plain language summaries, yes.

31

00:03:33.310 --> 00:04:01.829

Karen Gainey: to see what they think about them in terms of what they like. Why, they read them. What's most useful, all of those sort of things. So I've put all of that together. And now I want to get an understanding from the journal publisher, side of things, how things operate, decisions, how they're made, and why and what really goes on behind the scenes, and any barriers or facilitators.

32

00:04:02.329 --> 00:04:14.820

Karen Gainey: At your end. That drive the publication of, and I'll use the term plain language summaries quite generically that drive the publication of these, or.

33

00:04:15.070 --> 00:04:26.800

Karen Gainey: conversely, plain language, summaries of publications which I know you do there at (publisher), to get a better understanding of of the you know the full picture

34

00:04:28.210 --> 00:04:29.399

Participant 19: Yeah, sounds, good.

35

00:04:29.610 --> 00:04:32.019

Karen Gainey: Yeah, and I really want to hear the

36

00:04:32.370 --> 00:04:34.819

Participant 19: The real story, the good, bad, the ugly

37

00:04:36.000 --> 00:04:58.119

Karen Gainey: just because it's my area where it says to people, please don't be afraid to offend me, if it's I know it's not the case with (publisher), because they're very supportive of this area. But if it's something negative, that's really what I need to hear, also that there's no role for them in this area, or this doesn't work. That's really useful.

38

00:04:58.530 --> 00:04:59.150

Karen Gainey: Yeah.

39

00:04:59.150 --> 00:04:59.830

Participant 19: Sounds good

40

00:05:00.080 --> 00:05:18.349

Karen Gainey: Yeah. So I understand. From. So please correct me if I'm wrong. But looking at what you do on your website, you head up plain language summaries. So can I just get an idea of what that really means

41

00:05:18.570 --> 00:05:19.550

Karen Gainey: and what

42

00:05:19.550 --> 00:05:21.300

Participant 19: Yeah, so

43

00:05:21.680 --> 00:05:40.299

Participant 19: my scope is anything plain language summaries. So from the abstracts to the full publications. But my main focus is definitely the full publications and developing the growth of those and the editor managing the editorial team for that as well

44

00:05:40.300 --> 00:05:40.960

Karen Gainey: Right.

45

00:05:42.430 --> 00:05:49.048

Participant 19: So at the moment at (publisher). We don't publish them across all journals. Because there's so many

46

00:05:50.169 --> 00:05:53.570

Participant 19: we have a subset of journals that do publish them. And

47

00:05:54.160 --> 00:06:03.160

Participant 19: my role is to yeah, make sure that our processes and standards are up to what's expected in the industry. And

48

00:06:03.280 --> 00:06:06.009

Participant 19: I'm growing the initiative as well. Essentially

49

00:06:06.620 --> 00:06:15.560

Karen Gainey: Yeah. Okay, so because you work for (publisher), don't you not represent any particular journal?

50

00:06:15.720 --> 00:06:20.870

Karen Gainey: No. So I used to work for (publisher), which is where? The yes.

51

00:06:20.870 --> 00:06:41.739

Participant 19: Started and then (name) acquired (publisher) at the end of 2023. So the 2024. My role was different to what it is, kind of heading into 2025, because I was essentially bringing together the 2 plain language initiatives from both companies. So it was quite a lot of like

52

00:06:41.780 --> 00:06:52.770

Participant 19: admin work and making sure the teams like on the processes were the same. But yeah, going 25. Then it's gonna look more about building what we have now

53

00:06:53.300 --> 00:06:58.739

Karen Gainey: Right? Okay. So I've spoken with (name)

54

00:06:59.000 --> 00:07:00.090

Participant 19: And

55

00:07:00.605 --> 00:07:01.120

Karen Gainey: No

56

00:07:01.950 --> 00:07:02.300

Participant 19: (name) will

57

00:07:02.911 --> 00:07:05.967

Karen Gainey: Yes. (name). Yeah. Yeah. From

58

00:07:07.190 --> 00:07:08.620

Participant 19: Yeah. I'm already

59

00:07:08.620 --> 00:07:12.870

Karen Gainey: About (publisher). Yeah, yeah.

60

00:07:13.500 --> 00:07:38.069

Karen Gainey: Which was, yeah. I was aware of them, but had no idea. That's where the concept of the Plsps really started, and (publisher) kind of have taken that on. So maybe.

Can you tell me a little bit about that transition and the attitudes as much as you. You feel comfortable from (publisher) in that transition, and moving forward

61

00:07:38.740 --> 00:07:59.556

Participant 19: Yeah, so I've been really positive. Everyone is open to. Well, they already have PLSPs. They already published PLSPs when they acquired future science group. But it was on a smaller scale. Because (publisher) really were kind of the market leaders in that article type.

62

00:08:00.550 --> 00:08:01.490

Participant 19: but

63

00:08:02.200 --> 00:08:28.516

Participant 19: so the team. They already have their own processes, and they were. They were very similar to ours. But it was just making sure that everything was aligned and everyone knew our processes on the journals that published them. And kind of take, almost taking the best from both initiatives to make the new initiative which has been really great. Everyone's been very open and like well receiving of it. And the team's been really good

64

00:08:29.160 --> 00:08:39.150

Participant 19: and then but the difference at (publisher) is. There's obviously thousands of journals, and there's a lot of people who maybe don't know what they are or haven't heard of them before.

65

00:08:39.150 --> 00:08:39.539

Karen Gainey: Means.

66

00:08:39.549 --> 00:08:44.032

Participant 19: So we've done quite a lot of internal education and outreach

67

00:08:44.769 --> 00:08:46.589

Participant 19: and we did a like we did

68

00:08:47.029 --> 00:08:53.959

Participant 19: a webinar, me and (name) did when we when I 1st joined to kind of explain more in depth about what

69

00:08:54.499 --> 00:08:59.680

Participant 19: pls and pls were to anyone, could come from the company. Pleased.

70

00:09:00.040 --> 00:09:11.639

Participant 19: So. But I mean, everyone's very got a very positive attitude about it. And it's kind of how can we make it work instead of if it's gonna work at all, which is great

71

00:09:11.640 --> 00:09:25.950

Karen Gainey: Okay, yeah, that's awesome. Can you tell me a little bit more about that? Because one of the things that's come up from a lot of editors who kind of put themselves, not just in the editorial

72

00:09:26.080 --> 00:09:30.939

Karen Gainey: position position, but themselves as authors. Kind of.

73

00:09:30.940 --> 00:09:56.789

Karen Gainey: And I know myself writing a pls. It's not really easy to do. I mean, I wrote one a few weeks ago. It took an hour and a half, and so I know it's something that's often left to the last minute with authors. And there's often a, you know, a bit of reluctance. And also, maybe it's not something many authors are aware of the

74

00:09:56.790 --> 00:10:15.869

Karen Gainey: value in writing, so I'm interested to hear how things have gone with your education or your reach out to the employees. The workshop which sounds positive, but any kind of particular feedback or thoughts people shared

75

00:10:16.660 --> 00:10:17.280

Karen Gainey: would be

76

00:10:18.930 --> 00:10:29.339

Participant 19: only people reaching out about the possibilities of doing it on their specific journals that maybe if they don't publish them that's when people have reached out, or

77

00:10:29.940 --> 00:10:40.150

Participant 19: about improving the quality and kind of what resources that they can then share with authors, for example, to help them write a pls

78

00:10:43.620 --> 00:10:46.892

Participant 19: But other than that, there, hasn't we? I haven't had any

79

00:10:48.120 --> 00:10:52.285

Participant 19: Anything kind of more rogue? Question wise

80

00:10:53.230 --> 00:10:54.210

Participant 19: From the upcoming

81

00:10:54.210 --> 00:10:57.040

Karen Gainey: Or the perspective, so much

82

00:10:57.040 --> 00:11:23.670

Participant 19: So, not from that, not from the internal editor. Perspective. But the author. Perspective again, outreach is something that we try to do, and we have quite a lot of guidance on (publisher's) website, how to publish how to publish how to Peer review how to have a patient author. And not this year. We're planning on doing more outreach webinars and things like that to

83

00:11:23.992 --> 00:11:30.950

Participant 19: kind of answer, because I guess one of the questions, or one of the industry conversations is.

84

00:11:31.280 --> 00:11:38.989

Participant 19: what's the right level, and how do you write to the right? I don't think there's a clear answer for that.

85

00:11:39.690 --> 00:11:46.369

Participant 19: but it's something that we're like always looking to like help authors with, especially for pls, because Plsp is slightly

86

00:11:47.031 --> 00:12:02.108

Participant 19: different in that usually they're sponsored articles, so they'll have kind of a writing team on them. So like medical pharmaceutical companies who were trained in that type of writing

87

00:12:02.860 --> 00:12:04.854

Participant 19: but pls definitely

88

00:12:06.650 --> 00:12:16.230

Participant 19: it's obviously author led. So it's a bit more tricky to kind of get the right level. So it's all about education and engagement with that type of content

89

00:12:18.120 --> 00:12:27.830

Karen Gainey: Is that because of the nature of the journals that have pls, they tend to because of their topics, they tend to

90

00:12:28.270 --> 00:12:30.010

Karen Gainey: yeah, content

91

00:12:30.690 --> 00:12:33.306

Participant 19: Yeah, it's because it's medicine and health.

92

00:12:33.680 --> 00:12:34.150

Karen Gainey: Yeah.

93

00:12:34.150 --> 00:12:34.650

Participant 19: So.

94

00:12:34.650 --> 00:12:35.010

Karen Gainey: Yeah.

95

00:12:35.370 --> 00:12:44.500

Participant 19: And there's a fee for standalone article, so it usually comes from articles sponsored by pharmaceutical companies.

96

00:12:44.620 --> 00:12:51.630

Participant 19: and obviously pharma companies are very keen to do this type of content and kind of patient, centered content as well

97

00:12:51.960 --> 00:12:58.452

Karen Gainey: Yep, that makes sense. Yeah, that actually has come up a few times.

98

00:12:59.850 --> 00:13:12.169

Karen Gainey: so I'm glad you mentioned that because I actually had forgotten. And that's really important, because that kind of comes into a different aspect of being able to pay a medical rider.

99

00:13:14.466 --> 00:13:15.480

Karen Gainey: Just the

100

00:13:15.680 --> 00:13:24.139

Karen Gainey: do. The medical writers liaise with. Do you know your team? Or do you just see the finished product

101

00:13:24.560 --> 00:13:35.260

Participant 19: We just see the finished product, so they'll just submit it, as any other article type would be submitted. But a lot most of the time. There is a

102

00:13:35.550 --> 00:13:41.659

Participant 19: medcoms kind of leading the communications between the authors and the Journal

103

00:13:43.470 --> 00:13:47.709

Participant 19: and we do offer our own separate writing service.

104

00:13:48.198 --> 00:13:55.839

Participant 19: But it doesn't get that much uptake. To be honest. Most of them are written and submitted like any other article type would be

105

00:13:56.350 --> 00:14:00.919

Karen Gainey: Yeah, yeah, is that much like the the (publisher) one

106

00:14:01.780 --> 00:14:03.089

Participant 19: I don't know about the (publisher) one

107

00:14:03.090 --> 00:14:10.414

Karen Gainey: Oh, okay, sorry. I forgot what I want to ask you.

108

00:14:12.820 --> 00:14:21.199

Karen Gainey: Oh, I want to ask you so I know, talking to. I think it was either (name) or (name) talking about

109

00:14:21.970 --> 00:14:39.490

Karen Gainey: in the earlier days in that transition period, that with the plsp or pls that they were only select journals so obviously (publisher)has hundreds, or maybe a thousand, just wondering what the

110

00:14:40.030 --> 00:15:00.259

Karen Gainey: thought is behind. Well, I remember them initially saying how the initial ones were selected, based on the type of journal being patient focused, or you know the the scope of it. But I guess, is there any plans moving forward to expand that, and then

111

00:15:00.270 --> 00:15:20.379

Karen Gainey: ideas on how? What criteria might be applied if it's the same criteria or different, and how that it might impact author instructions. And is there a need to kind of keep those quite consistent or harmonized across the group

112

00:15:21.340 --> 00:15:33.249

Participant 19: I think. For psp, it is because it's a specific article type. So to me it should be the same. No matter the publisher as well, or very similar

113

00:15:34.059 --> 00:15:39.510

Participant 19: So (name) and I have actually been working with (name) and (name) and (Publisher).

114

00:15:40.450 --> 00:15:51.960

Participant 19: to kind of harmonize guidance with open pharma. So we we've got an abstract coming out at is Map annual late in a couple of months.

115

00:15:52.090 --> 00:15:54.270

Participant 19: That shows

116

00:15:56.480 --> 00:16:03.279

Participant 19: that that kind of shows the work that we've done in that space, basically to come up with industry guidance for Plsp article type

117

00:16:03.980 --> 00:16:05.610

Karen Gainey: Oh, right!

118

00:16:05.610 --> 00:16:16.139

Participant 19: So I think if that was to roll, I mean so at the moment. Psps are in about 60 journals at (publisher), or within collection. I believe that that was

119

00:16:16.420 --> 00:16:23.549

Participant 19: it. Those journals are all have in-house editor teams

120

00:16:24.420 --> 00:16:28.750

Participant 19: published like a span across healthcare. Yeah.

121

00:16:28.910 --> 00:16:34.605

Participant 19: think it was just it. It was a sensible place to start. This was before I joined

122

00:16:34.940 --> 00:16:35.680

Karen Gainey: Gotcha

123

00:16:36.720 --> 00:16:56.259

Participant 19: But I mean there's always plans, you know, if someone, if a client gets in touch a sponsor of an article and asks if we've got a journal in X topic, and it's not one that we do. I can always reach out to the manager of the journal and say, Is this something of interest and kind of build, a picture of if it would be

124

00:16:57.430 --> 00:17:00.046

Participant 19: if Plsps would be like

125

00:17:00.800 --> 00:17:05.050

Participant 19: a good article type for that journal, and if they are, then they can get added on

126

00:17:06.940 --> 00:17:09.530

Participant 19: So there's always scope to

127

00:17:10.380 --> 00:17:30.860

Participant 19: publishing more journals. It's just controlling the rollout. Essentially make sure it makes sense to the journal. The processes work, because a lot of journals have

external editor in chiefs that make the decisions on the journals, for example, whereas what at the moment Nsp's are in journals where the editor in house has that level of control. So it's just

128

00:17:32.140 --> 00:17:32.720

Participant 19: and yeah

129

00:17:32.720 --> 00:17:41.079

Participant 19: involved in the decision making is educated on what Psp's are, and the pro because it is slightly different. The process and things like that

130

00:17:41.450 --> 00:17:46.530

Karen Gainey: Gotcha. So that's quite a deliberate decision to keep

131

00:17:46.530 --> 00:17:47.000

Participant 19: Yeah.

132

00:17:47.270 --> 00:17:50.000

Karen Gainey: Especially in that rollout. Yeah.

133

00:17:50.000 --> 00:17:57.240

Participant 19: Yeah, in my, my, I mean my, I would love pls and pls piece to be on all journals. But

134

00:17:57.390 --> 00:18:01.570

Participant 19: it's a slower process than that.

135

00:18:01.570 --> 00:18:08.829

Karen Gainey: Yeah, yeah. Understand, has have you done any evaluation on them yet, or any plans

136

00:18:09.877 --> 00:18:12.159

Participant 19: Would you mean in terms of metrics and things like that?

137

00:18:12.160 --> 00:18:17.055

Karen Gainey: Yeah, metrics or any other like evaluating any

138

00:18:21.470 --> 00:18:25.069

Karen Gainey: yeah, like downloads or any other?

139

00:18:25.820 --> 00:18:33.695

Karen Gainey: I mean, it's hard. It's what I'm gathering is, these things are really hard to track now that everything's open access.

140

00:18:34.430 --> 00:18:41.380

Karen Gainey: But wondering if you had any thoughts on how these things can be evaluated.

141

00:18:41.630 --> 00:18:51.260

Karen Gainey: Social media. That sort of thing. Or if that's even being you utilized

142

00:18:52.020 --> 00:19:10.992

Participant 19: Yeah, so (publisher) metrics is something that we we're always keen to share, because I think it's not that common in publishing to be that open with metrics. So it's something that we, you know, it's it's we we know is beneficial to our offers and sponsors, and something that we want to share when we can.

143

00:19:12.300 --> 00:19:19.719

Participant 19: because it's open access. Yeah, a lot. Also because it's patient. Well, a lot of it's patient, aimed content. We do get asked quite a lot

144

00:19:20.610 --> 00:19:33.059

Participant 19: if patients are reading it. That's the main question. How do you know it's reaching the right audience with an academic journal? And I like you said because it's open access. It's not. We can't see who's reading the content.

145

00:19:33.340 --> 00:19:34.199

Participant 19: Yeah, we can.

146

00:19:34.560 --> 00:20:01.409

Participant 19: We can get a general idea because we can get the source of where the traffic's coming from. So we know if it's a more general audience, if it's through, Google, for example, than if it's through pubmed or through publisher websites. And we've we've had metrics before, where it's like 40% comes from Google for a Plsp whereas it's on its head for academic articles. So that would be that traffic would be coming from pubmed. For like a research article, for example.

147

00:20:01.500 --> 00:20:24.049

Participant 19: yeah, we know it is a kind of more general method of accessing the content. And we know we obviously share them with patient groups when they're published. So it is going directly to groups to to share if they want to, and patient groups, we know, have included them in their newsletters and in their own social media, and we publish on our social media, as well

148

00:20:24.970 --> 00:20:25.890

Karen Gainey: Right.

149

00:20:25.890 --> 00:20:27.149

Participant 19: We do as much as

150

00:20:27.540 --> 00:20:31.729

Participant 19: we do well, as much as we can. We do a lot to get it out there. And we're

151

00:20:31.730 --> 00:20:33.049

Karen Gainey: Yeah, yeah.

152

00:20:33.390 --> 00:20:46.578

Participant 19: Something I'm keen to now that we're more settled is I'm keen to kind of build a better picture of how patients are using the content so kind of getting feedback from the patient groups that we're sending them to, and

153

00:20:47.540 --> 00:21:01.839

Participant 19: making sure that we're keeping track of of when it's been shared, and what's been shared and kind of may maybe even potentially, doing a survey or something in the this year, at some point, just to kind of build a better, more like qualitative

154

00:21:02.150 --> 00:21:02.830

Karen Gainey: Yeah.

155

00:21:03.260 --> 00:21:11.450

Participant 19: That of feedback, of just how things are being used because we do get asked that question quite a lot. And then, in terms of general metrics. We this is quite old

156

00:21:11.700 --> 00:21:16.080

Participant 19: data now, because it was from 2023. But we looked at

157

00:21:16.490 --> 00:21:31.140

Participant 19: 150 plsp's have been published since 2020, and they'd received 300,000 downloads, or over 300,000 downloads in total. So averaging about 2,000 downloads per plsp, some get more, some get less.

158

00:21:31.140 --> 00:21:31.930

Karen Gainey: Yeah.

159

00:21:31.930 --> 00:21:40.770

Participant 19: And last year, kind of end. Q. 3 q. 4. Last year we looked at how much

160

00:21:41.280 --> 00:21:45.258

Participant 19: influence, having a extender on a Plsp. Would have

161

00:21:45.700 --> 00:21:46.390

Karen Gainey: Yep.

162

00:21:46.590 --> 00:21:49.689

Participant 19: Do you like a browser extension?

163

00:21:50.240 --> 00:21:57.820

Participant 19: No. So sorry. Like publish publication extenders. So like a video or podcast? Or a translation

164

00:21:58.360 --> 00:21:59.250

Karen Gainey: Oh!

165

00:21:59.250 --> 00:22:00.750

Participant 19: Supplements, the Pr.

166

00:22:00.750 --> 00:22:01.550

Karen Gainey: Okay.

167

00:22:03.480 --> 00:22:09.000

Participant 19: We basically found that having one made.

168

00:22:09.150 --> 00:22:13.039

Participant 19: I think it's a hundred 40% of the downloads like an increase.

169

00:22:13.475 --> 00:22:23.370

Participant 19: And we were shocked, so we didn't think it would be that much. We knew it would be well, we we thought it would be an increase in views, but it was well over a hundred percent well over double the views.

170

00:22:23.802 --> 00:22:38.800

Participant 19: So that was interesting. Those that people, if if there's I mean there's gonna be influencing factors. So, for example, the ones with the funding to pay for that type of content, it probably is a more is a bigger trial. That's gonna have a bigger impact, anyway.

171

00:22:38.800 --> 00:22:39.180

Karen Gainey: Yeah.

172

00:22:40.460 --> 00:22:40.859

Participant 19: Yeah, sure.

173

00:22:40.860 --> 00:22:54.059

Participant 19: Not only are they looking for Plsp content, but they they want it in more different formats, whether that's a video and audio, or in a different language, and it makes it. It definitely increases the reach of a publication

174

00:22:54.490 --> 00:22:58.800

Karen Gainey: Okay, yeah, it's oh, that's so interesting.

175

00:22:59.563 --> 00:23:07.240

Karen Gainey: Well, if you could get that qualitative survey done by the end of May, that'd be great for my thesis.

176

00:23:07.865 --> 00:23:08.645

Karen Gainey: Bye.

177

00:23:10.760 --> 00:23:13.880

Participant 19: I mean, it's something we want to do. But it's just something that yeah, M.

178

00:23:14.250 --> 00:23:15.350

Participant 19: No, I

179

00:23:15.680 --> 00:23:16.939

Karen Gainey: I'm joking.

180

00:23:18.600 --> 00:23:36.879

Karen Gainey: But yeah, no, that's I'll really look out for that abstract, although if you think of it, I'd really love for you to send that to me about the guidelines that you've been working on with open pharma. That'd be really, really interesting, really topical.

181

00:23:37.960 --> 00:23:42.046

Karen Gainey: So do you have any?

182

00:23:42.580 --> 00:23:58.780

Karen Gainey: I remember seeing I thought it was (publisher). But now I'm thinking it may have been (publisher), but I've lost the link a website where it showed a list of consumer groups.

183

00:23:59.730 --> 00:24:06.030

Karen Gainey: as I remember, one was the ME Society, or something of of the (country).

184

00:24:08.160 --> 00:24:14.810

Karen Gainey: yeah, if you have a list of the consumer groups that you send summaries, too.

185

00:24:15.530 --> 00:24:18.530

Karen Gainey: That'd be really useful just for my

186

00:24:18.530 --> 00:24:20.439

Participant 19: You mean application groups.

187

00:24:20.440 --> 00:24:22.690

Karen Gainey: Patient. Groups, sorry. Yeah.

188

00:24:22.690 --> 00:24:29.079

Participant 19: Yeah, yeah, we'll be. I'm sure I'll be able to. There, just a couple of examples.

189

00:24:29.080 --> 00:24:35.790

Participant 19: Look for relevant groups, whether that's on social media or using Google

190

00:24:35.790 --> 00:24:36.330

Karen Gainey: Oh!

191

00:24:36.330 --> 00:24:37.140

Participant 19: Funds.

192

00:24:37.780 --> 00:24:45.509

Karen Gainey: So it's not a standard list. It's more when a Plsp comes out. You look at the time who that might be relevant for

193

00:24:46.000 --> 00:24:59.070

Participant 19: Yeah. So we have a, we keep a tracker of ones that we've sent them out to. Just so we have a list of groups to hand. So they'll take from the existing list that credit just keeps building, because they'll still keep looking for

194

00:24:59.230 --> 00:25:00.179

Participant 19: right. I've been great

195

00:25:00.180 --> 00:25:00.810

Karen Gainey: Shop.

196

00:25:01.090 --> 00:25:06.090

Karen Gainey: Great. Yeah, if you wouldn't mind just a couple of examples

197

00:25:06.700 --> 00:25:29.969

Karen Gainey: I can highlight that in my paper that'd be but I I will make sure there's no identifying information. Obviously, if that's alright. But that's a great use, because that's I've always thought pls and plsp are underutilized in that sort of area. So I really want to show them being disseminated. I think that's really important.

198

00:25:30.389 --> 00:25:37.580

Karen Gainey: What are your thoughts, I guess more on the future of things like generative AI as a tool

199

00:25:37.720 --> 00:25:43.800

Karen Gainey: for either authors or at the publishing point.

200

00:25:44.120 --> 00:25:45.580

Karen Gainey: I know if you so

201

00:25:46.320 --> 00:25:51.149

Participant 19: Personally, aside from T. And A. I think it is

202

00:25:51.990 --> 00:25:58.271

Participant 19: this, it is going to be used at some point like more consistently. But

203

00:25:58.690 --> 00:26:00.380

Karen Gainey: We already being used

204

00:26:00.870 --> 00:26:25.210

Participant 19: Well, people do exactly. People do use it, and it's kind of got, I think, with pls, there's some research at the last is map EU meeting I was at, and they were analyzing. If people could recognize when one had been generated by AI or not, or that the quality or something can. Essentially the quality of the AI ones is comparable now to kind of a 1st draft of one.

205

00:26:27.230 --> 00:26:39.925

Participant 19: But it's still it's not. It's not error free, and it's not, you know. It still needs someone to go through it and edit it. But I think if it can be utilized as a time saver

206

00:26:40.630 --> 00:26:56.989

Participant 19: and a resource saver, then it it could eventually be a positive thing. It's not something that we implement at the moment (publisher) for any pls content. It's not something that we're averse to. You know. We have working groups internally that are exploring different things.

207

00:26:57.630 --> 00:27:06.230

Participant 19: but at the moment we don't, and any authors that would use it would follow (publisher) General AI guidance, which

208

00:27:06.480 --> 00:27:15.146

Participant 19: involves things like appropriately citing it and explaining when it's been used and how it's been used. So at the moment it's pretty general

209

00:27:15.800 --> 00:27:20.409

Participant 19: in terms of if you're an author, and we don't use it internally for pls at the moment

210

00:27:20.840 --> 00:27:21.900

Karen Gainey: Yeah, yeah.

211

00:27:21.900 --> 00:27:27.250

Participant 19: But I mean, I can see its heading that way because it it just is, yeah, yeah.

212

00:27:27.250 --> 00:27:36.782

Participant 19: making sure that the quality is right. And you've still got kind of the approval of a person, because otherwise it could be some very rogue things being put out.

213

00:27:37.540 --> 00:27:40.520

Participant 19: Yeah, it's pretty much the sentiment of everybody. Yeah.

214

00:27:41.180 --> 00:27:44.349

Karen Gainey: Good tool, but still needs a human.

215

00:27:44.520 --> 00:27:46.830

Karen Gainey: That's time to look at it. Yeah.

216

00:27:46.830 --> 00:27:49.479

Karen Gainey: Can't rely on it completely.

217

00:27:50.140 --> 00:27:57.880

Karen Gainey: yeah, yeah, which which makes sense. I mean, do you think that's something that

218

00:27:58.560 --> 00:28:08.129

Karen Gainey: from your perspective, or (publisher), you prefer that to come from your end, or the author, or it wouldn't really matter as long as the product was good.

219

00:28:09.522 --> 00:28:14.730

Participant 19: I think it will end up, probably coming from both sides. I think

220

00:28:15.000 --> 00:28:20.980

Participant 19: there's the level of I mean, it's not my bag really, but in terms of keeping data secure.

221

00:28:21.180 --> 00:28:24.859

Participant 19: which I think is a challenge

222

00:28:25.200 --> 00:28:39.365

Participant 19: kind of if an author doesn't understand the the consequences potentially of that, like putting their data in kind of an open AI system. But that's that's the same for anything, not just scientific data.

223

00:28:41.190 --> 00:28:48.820

Participant 19: so there's the death. There's definitely risks associated, and I think it will come with again education of authors and them understanding

224

00:28:50.180 --> 00:28:53.906

Participant 19: how it works and it, and internally as well.

225

00:28:54.990 --> 00:28:59.510

Participant 19: But I can't. I feel like it. It's gonna end up coming from both sides

226

00:29:00.000 --> 00:29:00.700

Karen Gainey: Yep.

227

00:29:00.880 --> 00:29:01.750

Karen Gainey: Yep.

228

00:29:02.480 --> 00:29:05.737

Participant 19: But we can. Only we can control one more than we control the other.

229

00:29:05.970 --> 00:29:19.300

Karen Gainey: Right? Yeah, of course. Yeah, of course. Would that be something like so obviously, Plsps are a separate article type. But with pls. Would

230

00:29:19.920 --> 00:29:25.770

Karen Gainey: (publisher) consider any AI. Use something that would need to be declared

231

00:29:26.640 --> 00:29:42.059

Participant 19: Yeah, so it would follow, which is, you have to declare it. You have to acknowledge what what stage it was at, and kind of the input that the system had and obviously the standard. I can't be an author on a paper.

232

00:29:42.410 --> 00:29:43.110

Karen Gainey: Right.

233

00:29:43.440 --> 00:29:45.849

Participant 19: Just be acknowledged as it being used

234

00:29:46.300 --> 00:29:47.600

Karen Gainey: Yep, yep,

235

00:29:52.240 --> 00:29:53.306

Karen Gainey: Just wanna

236

00:29:55.950 --> 00:30:20.609

Karen Gainey: I know this might be a bit tricky because you're at the publisher level, not the journal level. So tell me if this is outside of your purvie. But one of the things I'm trying to understand is the place that pls have in the submission portals, and it seemed to vary from journal to journal, publisher to publisher.

237

00:30:21.560 --> 00:30:27.590

Karen Gainey: But it seems to have an impact whether there's a separate field

238

00:30:27.820 --> 00:30:34.010

Karen Gainey: for the pls as opposed to it being part of just the the manuscript.

239

00:30:35.383 --> 00:30:39.330

Karen Gainey: Yeah. So

240

00:30:40.240 --> 00:30:52.310

Karen Gainey: do you have any thoughts or understanding of how that operates? Or if that's across the board with (publisher) as a process, or if that's more journal specific

241

00:30:52.940 --> 00:30:58.440

Participant 19: You know what? I'm actually not sure where it sits on our submission system. But I

242

00:30:58.660 --> 00:31:04.540

Participant 19: it won't be journal specific. I think it will be consistent across across journals.

243

00:31:04.730 --> 00:31:08.460

Participant 19: I don't know. Actually, if there's a separate field, or if it's just, input

244

00:31:08.840 --> 00:31:11.370

Participant 19: I can look that up because it would only take a

245

00:31:11.620 --> 00:31:16.190

Participant 19: 10 min to find out. But yeah, yeah, that's

247

00:31:22.888 --> 00:31:26.069

Participant 19: Do you, scholar one? Or is it a different? Yeah.

248

00:31:26.270 --> 00:31:38.940

Karen Gainey: Yeah. So I don't know whether that's so I've been told these things are quite easy to turn on and off in the portals, so I don't know whether those

249

00:31:39.320 --> 00:31:45.400

Karen Gainey: trying to just understand how all of this fits together, and when in the discussion it's a maid

250

00:31:46.650 --> 00:31:56.830

Karen Gainey: whether and how important it is, I guess, for, say, (publisher), to have things be very homogeneous

251

00:31:57.230 --> 00:31:59.609

Karen Gainey: in the way things are done.

252

00:32:00.440 --> 00:32:03.980

Participant 19: Yeah, we definitely like to keep our processes consistent.

253

00:32:05.150 --> 00:32:13.129

Participant 19: Look where where it goes. Because we do. We ask them to be submitted, for they undergo peer review with the manuscript, right

254

00:32:13.130 --> 00:32:14.980

Karen Gainey: That was my next question. Yeah.

255

00:32:14.980 --> 00:32:17.039

Participant 19: Yeah, I don't know if it's a specific

256

00:32:17.260 --> 00:32:21.720

Participant 19: place, or if it, we just ask that it's put in with the main document.

257

00:32:22.380 --> 00:32:29.060

Karen Gainey: So, I guess. Do you know, if it wasn't included, would it be?

258

00:32:29.630 --> 00:32:41.529

Karen Gainey: Would there be a prompt say from the the editor who's reviewing, reviewing it, to then ask for it before it goes to peer review. Would that just depend on whether it's mandatory or not? For that journal

259

00:32:42.120 --> 00:32:45.329

Participant 19: So they're not mandatory any channel. Yeah.

260

00:32:45.700 --> 00:32:47.540

Karen Gainey: For any channel. Okay?

261

00:32:47.540 --> 00:32:51.870

Participant 19: No, some editor that's probably editor specific. If they prompt

262

00:32:52.270 --> 00:33:04.410

Karen Gainey: Yep, gotcha so do you know if they if you get many peer review comments on the pls

263

00:33:05.330 --> 00:33:19.707

Participant 19: So not as much on the pls. I don't think we get quite a lot on the standalone articles. Because that's what the reviewers are fully looking at, but I think for the the pls, and it's not we don't have

264

00:33:20.700 --> 00:33:33.979

Participant 19: people necessarily experienced in plain language, reviewing pls because they're peer reviewed with the main article. So it would be the subject specialists that are looking at it, which is where the challenge kind of comes in of making sure it's an appropriate

265

00:33:34.570 --> 00:33:38.359

Participant 19: level of plain language. It's definitely more difficult with

266

00:33:38.980 --> 00:33:43.749

Participant 19: pls within an article than standalone article just because of the review processes

267

00:33:44.150 --> 00:33:52.739

Karen Gainey: Yeah, okay, so how does it work with the subject specialists? Is that the but like a non-expert person

268

00:33:53.590 --> 00:33:59.320

Participant 19: No, so those would be. You review the content of the actual scientific article.

269

00:34:00.930 --> 00:34:04.849

Participant 19: They they would just review the full submission, including the Pls.

270

00:34:05.110 --> 00:34:05.910

Participant 19: Gotcha again

271

00:34:05.910 --> 00:34:06.630

Karen Gainey: Okay.

272

00:34:06.630 --> 00:34:11.560

Participant 19: Like reviewer, dependent. How engaged they are with that type of content as well

273

00:34:12.000 --> 00:34:20.723

Karen Gainey: Right. Okay, so do you know, if there's cause sorry it's a while since I looked at your guidelines.

274

00:34:23.580 --> 00:34:34.900

Karen Gainey: but I know they're they are very. They're very detailed. Do you know, if there's anything in the Peer Review guidelines that details pls, or

275

00:34:35.580 --> 00:34:38.929

Participant 19: So we have separate guidance for plsp.

276

00:34:39.199 --> 00:34:41.269

Participant 19: Yeah, let's fine. Yeah.

277

00:34:41.570 --> 00:34:47.970

Participant 19: But I actually don't know in terms of the guidance that a general reviewer would get if it's got pls

278

00:34:48.770 --> 00:34:49.550

Karen Gainey: Yep.

279

00:34:50.690 --> 00:34:58.219

Participant 19: (name) will probably be able to answer this better, because she would have worked on setting up pls in the journals before I joined

280

00:34:58.650 --> 00:35:02.750

Karen Gainey: I will just make a note, and I'll ask (name) cool.

281

00:35:03.150 --> 00:35:05.630

Karen Gainey: I'm talking to (name) on Thursday.

282

00:35:07.490 --> 00:35:13.729

Karen Gainey: I'm asking about peer review guidelines great.

283

00:35:16.170 --> 00:35:20.541

Karen Gainey: So, looking at the plsp's,

284

00:35:21.390 --> 00:35:25.469

Karen Gainey: so they're a separate article type with their own guidelines.

285

00:35:27.170 --> 00:35:32.630

Karen Gainey: Are they written by the author, or they're written by a separate team

286

00:35:33.000 --> 00:35:34.470

Participant 19: Or good

287

00:35:35.730 --> 00:35:36.390

Karen Gainey: Pace.

288

00:35:37.618 --> 00:35:50.889

Participant 19: So they're written by. They're they're written by the authors, but they're supported by usually not always, but usually supported by like writing agencies and medical communications, companies through pharmaceutical companies.

289

00:35:51.330 --> 00:35:55.499

Karen Gainey: Right. They're the ones that tend to have those sponsored, those sponsored articles

290

00:35:55.780 --> 00:36:10.650

Participant 19: Yeah, they. They tend to have support for PLSPs in general. We had a institution PLSP submitted from universities. But majority of them will have extra support

291

00:36:11.140 --> 00:36:15.677

Karen Gainey: Yeah, what do you have any sense of the quality, or

292

00:36:16.890 --> 00:36:23.099

Karen Gainey: How if they, if they, if they're suitable for what they're meant to be

293

00:36:24.130 --> 00:36:26.010

Participant 19: For work.

294

00:36:27.255 --> 00:36:41.150

Participant 19: So usually they're submitted at a quality that's high, of good enough standard to go through to peer review and then we have 2 reviewers. Look at it for plain language. That's patients, patient advocates and

295

00:36:41.210 --> 00:36:58.060

Participant 19: language specialists. And then we get one usually, unless we need to. But we'll get one subject reviewer. So an academic reviewer who basically compares if it's accurately summarizing the original publication to make sure it's

296

00:36:58.060 --> 00:36:58.670

Karen Gainey: Yup!

297

00:36:59.300 --> 00:37:03.200

Participant 19: Okay, and we we get.

298

00:37:03.440 --> 00:37:09.149

Participant 19: we usually get more comments on the language than we do on the scientific side.

299

00:37:09.960 --> 00:37:15.779

Participant 19: can be extensive, but then I wouldn't. It's rare that we would get a major

300

00:37:17.630 --> 00:37:37.340

Participant 19: review. But we do get a lot of comments on language, and what would sound better, and maybe this word would be better, or this phrase comes across badly, or something which is really helpful. It's why we have that step, especially because there's so much debate on what actually is plain language. So if we get people who

301

00:37:37.670 --> 00:37:42.619

Participant 19: target audience to look at the content, at least we can say we have that checkpoint to.

302

00:37:43.140 --> 00:37:48.829

Participant 19: Oh, sure. But yeah, oh, it's also interesting. It's such a subjective

303

00:37:49.380 --> 00:37:58.080

Participant 19: thing, you know. There is things that are obviously not plain language enough, but sometimes it is just a difference of opinion, especially with

304

00:38:00.160 --> 00:38:14.909

Karen Gainey: Yeah, and and non English speakers. A factor as well. Do do you find the things they're correcting? Are? Is it medical jargon? Or more complex words, or something else

305

00:38:16.940 --> 00:38:17.640

Participant 19: Depends on

306

00:38:17.640 --> 00:38:19.790

Karen Gainey: Way it's expressed like

307

00:38:19.790 --> 00:38:20.429

Participant 19: It's a lot

308

00:38:20.430 --> 00:38:21.750

Karen Gainey: Sentence or something.

309

00:38:22.190 --> 00:38:26.023

Karen Gainey: One word might be tweaked to, to use a different word.

310

00:38:26.950 --> 00:38:35.060

Participant 19: Or adding maybe a bit more context around something or a definition of something, or even sometimes, if

311

00:38:35.410 --> 00:38:48.589

Participant 19: most people submit them, just as a text article to then get created into the laid out version. Some people submit the laid out version. So then there'll be comments on the layout and the the colors used, and the figures and things like that

312

00:38:49.460 --> 00:38:51.070

Karen Gainey: Oh, that, okay.

313

00:38:51.250 --> 00:39:07.109

Karen Gainey: thanks. That's really, really interesting. And so where I get to really get into the nitty gritty of someone who actually knows about that stuff. So that's really really interesting to me. So yeah.

314

00:39:07.720 --> 00:39:13.879

Participant 19: We found with our language translations of this content as well. It took us quite a while to

315

00:39:14.360 --> 00:39:18.010

Participant 19: find the right translators, because we.

316

00:39:18.120 --> 00:39:20.850

Participant 19: the feedback we were getting at the start was that it?

317

00:39:21.280 --> 00:39:27.189

Participant 19: It was was this written by AI, which was certainly what it wasn't. So we were like. That's really interesting. And

318

00:39:27.190 --> 00:39:27.620

Participant 19: well.

319

00:39:27.620 --> 00:39:36.890

Participant 19: we kind of found when we dug into a bit more was that it was being translated literally, which is what you would do for a standard language translation,

320

00:39:37.720 --> 00:39:50.600

Participant 19: from one language to the other, but it basically would lose its plain language aspect because it was being translated so literally. So we ha! We changed translators, and actually

321

00:39:50.870 --> 00:39:54.870

Participant 19: added in an additional step of review, where they'd compare the

322

00:39:55.100 --> 00:40:00.180

Participant 19: language, the new language to a plain language brief instead of the English version

323

00:40:00.340 --> 00:40:03.319

Participant 19: to make sure that it still came across

324

00:40:03.830 --> 00:40:06.610

Participant 19: as plain language in the new language.

325

00:40:06.780 --> 00:40:07.410

Participant 19: Yeah.

326

00:40:07.580 --> 00:40:07.750

Karen Gainey: Yeah.

327

00:40:07.750 --> 00:40:18.290

Participant 19: That seems to have solved. We don't. We no longer get comments asking if it's AI written. But it was so interesting that the original translation just wasn't

328

00:40:18.510 --> 00:40:23.859

Participant 19: cutting the mustard because it was, it just lost its simple factor

329

00:40:24.210 --> 00:40:30.650

Karen Gainey: Yeah, yeah, that's actually consistent with what a couple of European editors have told me.

330

00:40:31.800 --> 00:40:54.700

Karen Gainey: and it kind of comes back to something I want to ask you about which is the label that you've used, or that (publisher) used, which is plain language summary, and whether that was deliberate or somewhat inherited, because I was speaking to someone from a European journal, and they use the words patient, summary, because he said, in

331

00:40:54.710 --> 00:41:02.020

Karen Gainey: in Europe, and this was in (country). They don't really understand the term plain language.

332

00:41:02.530 --> 00:41:08.879

Karen Gainey: and they don't have a ironically, a plain language, equivalent to the term plain language.

333

00:41:09.050 --> 00:41:25.010

Karen Gainey: but patient, summary worked well, but when I spoke to people who read these summaries they had a lot of resistance around the word patient because they felt it was patronizing, and they didn't identify necessarily as patients.

334

00:41:26.320 --> 00:41:41.069

Karen Gainey: And so being in the (country) just wondering, yeah, on your thoughts on that term, because what people said was the term, or whatever it was, had an impact on whether they would read further

335

00:41:41.650 --> 00:41:49.709

Participant 19: So it's not so. It's definitely something that I've inherited. But I agree, it's it's interesting, I think.

336

00:41:50.550 --> 00:41:56.839

Participant 19: from obviously from my perspective, which is, I'm immersed in the plaint language, summary side.

337

00:41:57.220 --> 00:42:00.620

Participant 19: That seems to be the most consistently used term for this.

338

00:42:01.020 --> 00:42:06.909

Participant 19: especially plsp articles. But you do you know there's so many different

339

00:42:07.200 --> 00:42:11.040

Participant 19: names, and that does make sense about patient summary, but

340

00:42:11.420 --> 00:42:15.700

Participant 19: also why people would want to use plain language summary. So I think.

341

00:42:16.320 --> 00:42:20.210

Participant 19: I think the key is making sure that each

342

00:42:21.340 --> 00:42:29.900

Participant 19: as long calling the same thing the same thing. So not using 2 different names, the same thing. But again, that's easier said than done.

343

00:42:30.580 --> 00:42:36.840

Participant 19: But it's also interesting, because it's it's her opinions of start have changed a bit. But

344

00:42:37.450 --> 00:42:48.479

Participant 19: it took on quite a while for the like, for pharmaceutical companies to get on board with plain language summaries a lot of them are now, and some of them are really kind of leading it, but

345

00:42:49.340 --> 00:42:57.960

Participant 19: if I think calling it a patient summary would introduce, make it even more complicated, almost because some, some, some.

346

00:42:58.760 --> 00:43:05.700

Participant 19: a lot of compliance revolves around, not it not being patient, aimed, content, more like that, not

347

00:43:05.700 --> 00:43:06.090

Karen Gainey: Yeah.

348

00:43:06.090 --> 00:43:06.660

Participant 19: Thanks.

349

00:43:06.970 --> 00:43:10.610

Karen Gainey: With regulations advertising. And yeah.

350

00:43:10.610 --> 00:43:16.159

Participant 19: And language, then, is at that level is quite key. If something is happening or not happening.

351

00:43:16.400 --> 00:43:23.429

Participant 19: Yeah, yeah. So it's it's interesting. It makes sense. Our patient summary does make sense. But

352

00:43:23.730 --> 00:43:41.177

Participant 19: plain language summaries like it's what I took on, and it's something that I think is quite well known now in the field here, other people's opinions on it. I've just I can send over when it comes out as well. And they are about how how many pls they've done? Because I have a pls mandate.

354

00:43:50.769 --> 00:44:03.700

Participant 19: So how successful that's been, and then kind of from the publisher side. How successful it's been publishing pls and kind of the challenges that we face, so like the education and things like that

355

00:44:03.700 --> 00:44:05.390

Karen Gainey: Oh, yeah. Fantastic!

356

00:44:05.390 --> 00:44:07.410

Participant 19: No, but we put yes, from

357

00:44:07.460 --> 00:44:14.650

Participant 19: abstract. We've published over a thousand pls in journals now.

358

00:44:15.150 --> 00:44:29.249

Karen Gainey: Wow, yeah, that's brilliant. Yeah, which? Yeah, those really nuanced insights are so valuable. And not easy to to kind of find. And unless you you kind of know where to look. Yeah, that

359

00:44:29.250 --> 00:44:29.610

Karen Gainey: yeah.

360

00:44:29.610 --> 00:44:31.729

Karen Gainey: Great, really great.

361

00:44:32.276 --> 00:44:43.760

Karen Gainey: Well, I actually started my thesis using the term lay summary. And it was only speaking to people, and they said, Oh, we associate that with religion, or chickens.

362

00:44:44.120 --> 00:44:53.061

Karen Gainey: or which took me a while to get, and that I changed the plain language after that, because it was more universal.

363

00:44:53.670 --> 00:45:01.780

Karen Gainey: but it seems labels either either describe what the thing is. It's plain language, or who it's for patience.

364

00:45:01.780 --> 00:45:02.560

Karen Gainey: Summary

365

00:45:04.253 --> 00:45:11.329

Karen Gainey: So that kind of really makes sense with what you've said. So I just want to wrap up

366

00:45:11.887 --> 00:45:19.770

Karen Gainey: and ask you where you think, or where you would like the future of this area to be

367

00:45:20.162 --> 00:45:21.729

Participant 19: In a dream World.

368

00:45:23.610 --> 00:45:32.380

Participant 19: (publisher). All our journals publishing it. Publishing pls. Content. Plsp. Content is well, particularly in medicine and health.

369

00:45:34.050 --> 00:45:52.290

Participant 19: and more publishers publishing the content as well. Yeah, I think it's an article type that's here to stay. Now, there's, I think, 4 publishers that do this type of content already, and the more the merrier, really, because it's the whole purpose of it is to

370

00:45:52.570 --> 00:46:00.030

Participant 19: make research more accessible to people that need it. So the more people that get on board

371

00:46:02.040 --> 00:46:12.329

Participant 19: the better. Really something that I'm working on with those publishers is, I don't know if (name) or (name) mentioned it. But it's called Pls Finder, or that's the name that we're working with at the moment.

372

00:46:12.830 --> 00:46:21.489

Participant 19: So that's essentially the idea of that is, it's like a Google or a pubmed, but for plain language, content, and that that

373

00:46:21.970 --> 00:46:27.350

Participant 19: in the future will be kind of the go to place to easily find

374

00:46:27.740 --> 00:46:31.421

Participant 19: whatever you're looking for, no matter who you are.

375

00:46:33.040 --> 00:46:38.410

Participant 19: in terms of plain language, content, and also kind of the

376

00:46:39.230 --> 00:46:51.830

Participant 19: the gateway that it. That type of content provides to get more patients who aren't involved in publications involved in publications. Whether that's as authors, readers, reviewers.

377

00:46:51.980 --> 00:46:54.969

Participant 19: it's a it's a really great access point

378

00:46:55.420 --> 00:47:05.660

Participant 19: for people who haven't had any prior experience. And then, you know, it'd be incredible if researched articles

379

00:47:06.100 --> 00:47:10.027

Participant 19: start to have more and more patient authorship, for example.

380

00:47:10.540 --> 00:47:17.430

Participant 19: And it is. It is, you know, the tide is turning, but it is publishing is quite slow moving machine

381

00:47:18.370 --> 00:47:31.190

Karen Gainey: Yeah, it it is, but it's I've I've co-designed a couple of pls with with a consumer, and it's it takes a bit more time, but it's really worthwhile. And

382

00:47:31.190 --> 00:47:31.690

Participant 19: And

383

00:47:31.690 --> 00:47:45.579

Karen Gainey: You know, and it was I learned so much out of it. But I think that pls finder when I 1st started this that was my vision, for where I'd like the future to go. So I was so excited to hear that that's happening. I think that's

384

00:47:45.580 --> 00:47:53.259

Karen Gainey: yes a 1 place repository is just, yeah, brilliant. So

385

00:47:53.260 --> 00:47:56.688

Participant 19: Yeah, now that we speak about it, it's all so excited

386

00:47:57.000 --> 00:48:00.110

Karen Gainey: Yeah. Yeah. Any idea when that'll be live.

387

00:48:00.980 --> 00:48:03.810

Participant 19: So we're planning on having well

388

00:48:04.554 --> 00:48:16.225

Participant 19: hoping to have something to show publicly by the (professional association meeting, which I is either in a month or 2 months. I think it might be end of April start of May.

389

00:48:17.140 --> 00:48:25.489

Participant 19: we're hoping to have something workable by then. But definitely this year it will be

390

00:48:26.610 --> 00:48:30.249

Participant 19: hopefully are publicly available

391

00:48:30.370 --> 00:48:40.980

Participant 19: search engine. I think the plan is to start it, to, to start it, maybe in a specific therapy area or something so, and then gradually build it out and out. So

392

00:48:40.980 --> 00:48:41.800

Participant 19: good news

393

00:48:42.440 --> 00:48:47.079

Karen Gainey: Yeah, and using what you've learned with the Plsp model

394

00:48:47.080 --> 00:48:47.410

Participant 19: Yeah.

395

00:48:47.410 --> 00:48:52.579

Karen Gainey: Starting small and building it gradually to make sure it's robust

396

00:48:52.790 --> 00:48:56.109

Participant 19: Yeah, exactly. And get user feedback. And things like that.

397

00:48:56.110 --> 00:49:03.651

Karen Gainey: Yeah, yeah. Oh, most definitely. That sounds super exciting. I will definitely watch that

398

00:49:04.440 --> 00:49:19.780

Karen Gainey: and all the best absolutely thrilled for you. I did mean to ask. Sorry one really quick thing, but super important. Do you know why the Pls. Aren't mandatory at Tnf.

399

00:49:20.890 --> 00:49:34.706

Participant 19: No, I don't. I don't know the decision behind it. Maybe when it was rolled out it was quite early days. Maybe they didn't want it as a blocker for any offers. But

400

00:49:36.180 --> 00:49:38.989

Participant 19: no, I wasn't party to those decisions.

401

00:49:39.500 --> 00:49:45.220

Karen Gainey: That's all right, that's what some have said. They were mandatory, and they saw incomplete submissions

402

00:49:45.630 --> 00:49:46.749

Participant 19: And that makes sense

403

00:49:46.750 --> 00:49:47.959

Karen Gainey: Optional and that change.

404

00:49:48.740 --> 00:49:56.829

Karen Gainey: So I wondered if that was the same. Yeah, okay, thank you so much. That's been brilliant. I appreciate it

405

00:49:56.830 --> 00:50:02.140

Participant 19: Been interested. I'll send you over the abstracts when I. When they get published. It should be next

406

00:50:02.140 --> 00:50:05.939

Karen Gainey: It's not perfect, awesome. Thank you again.

407

00:50:06.240 --> 00:50:09.589

Karen Gainey: No worries anything else. Just shoot it across

408

00:50:09.910 --> 00:50:11.020

Participant 19: Yeah, I will do.

409

00:50:11.300 --> 00:50:12.689

Karen Gainey: All right. Have a good week